Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

Advances in ovarian cancer, from biology to treatment

Nature Cancer volume 2, pages 6–8 (2021)Cite this article

Subjects

Recent preclinical and clinical research has led to exciting advances related to high-grade serous ovarian cancer, from examining its cellular origins to gaining insight into DNA-damage-repair mechanisms that may be leveraged for therapies. Furthermore, studies have demonstrated clinical benefit for inhibition of the polymerase PARP and modulation of the cell cycle, and have identified molecular features related to therapeutic response.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Key research achievements and emerging priorities in 2020.

References

  1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. CA Cancer. J. Clin. 68, 394–424 (2008).

    Article  Google Scholar 

  2. Zhang, S., Dolgalev, I., Zhang, T., Ran, H., Levine, D. A. & Neel, B. G. Nat. Commun. 10, 5367 (2019).

    Article  Google Scholar 

  3. Lõhmussaar, K. et al. Nat. Commun. 11, 2660 (2020).

    Article  Google Scholar 

  4. Patch, A. M. et al. Nature 521, 489–494 (2015).

    Article  CAS  Google Scholar 

  5. Olivieri, M. et al. Cell 182, 481–496 (2020).

    Article  CAS  Google Scholar 

  6. Farkkila, A. et al. Nat. Commun. 11, 1459 (2020).

    Article  CAS  Google Scholar 

  7. Oza, A. M. et al. Clin. Cancer Res. 26, 4767–4776 (2020).

    Article  CAS  Google Scholar 

  8. Lheureux, S. et al. J. Clin. Oncol. 37, 5518 (2019).

    Article  Google Scholar 

  9. Liu, J. F. et al. J. Clin. Oncol. 38, 6009 (2020).

    Article  Google Scholar 

  10. Trillsch, F. et al. J. Clin. Oncol. 38, 6068 (2020).

    Article  Google Scholar 

  11. Banerjee, S. et al. Ann. Oncol. 31, S613 (2020).

    Article  Google Scholar 

  12. Du Bois, A. et al. J. Clin. Oncol. 38, 6000 (2020).

    Article  Google Scholar 

  13. Zang, R. et al. J. Clin. Oncol. 38, 6001 (2020).

    Article  Google Scholar 

  14. Coleman, R. L. et al. N. Engl. J. Med. 381, 1929–1939 (2019).

    Article  Google Scholar 

  15. Reid, F. et al. Int. J. Gynecol. Cancer ijgc-2019-000983 (2020).

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

    Michelle McMullen, Katherine Karakasis & Amit M. Oza

  2. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

    Robert Rottapel

  3. Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

    Robert Rottapel

  4. Department of Medicine, University of Toronto, Toronto, Ontario, Canada

    Robert Rottapel

  5. Department of Immunology, University of Toronto, Toronto, Ontario, Canada

    Robert Rottapel

  6. Division of Rheumatology, St. Michael’s Hospital, Toronto, Ontario, Canada

    Robert Rottapel

Authors
  1. Michelle McMullen
    View author publications

    Search author on:PubMed Google Scholar

  2. Katherine Karakasis
    View author publications

    Search author on:PubMed Google Scholar

  3. Robert Rottapel
    View author publications

    Search author on:PubMed Google Scholar

  4. Amit M. Oza
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Amit M. Oza.

Ethics declarations

Competing interests

A.M.O. declares grants to his institution from AstraZeneca, outside the submitted work, and membership on uncompensated steering committees with AstraZeneca and Clovis and uncompensated advisory role with AstraZeneca and GSK. A.M.O. is principal investigator on investigator-initiated trials with agents from AstraZeneca, GSK and Clovis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McMullen, M., Karakasis, K., Rottapel, R. et al. Advances in ovarian cancer, from biology to treatment. Nat Cancer 2, 6–8 (2021). https://doi.org/10.1038/s43018-020-00166-5

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s43018-020-00166-5

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing